Prérequis nécessaires pour la mise en place de protocoles de recherche clinique évaluant des thérapies cellulaires et géniques par lymphocytes T dotés de récepteur chimérique à l’antigène (CAR T-cells) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Tipton, 2016, [How we harmonize HSCT clinical practices among the SFGM-TC centers], Bull Cancer, 103, S193, 10.1016/j.bulcan.2016.09.006 Gauthier, 2017, Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives, Curr Res Transl Med, 65, 93, 10.1016/j.retram.2017.08.003 Zeltsman, 2017, CAR T-cell therapy for lung cancer and malignant pleural mesothelioma, Transl Res, 187, 1, 10.1016/j.trsl.2017.04.004 Klampatsa, 2017, Intracavitary “T4 immunotherapy” of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells, Cancer Lett, 393, 52, 10.1016/j.canlet.2017.02.015 Adusumilli, 2014, Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity, Sci Transl Med, 6, 261ra151, 10.1126/scitranslmed.3010162 Beatty, 2014, Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies, Cancer Immunol Res, 2, 112, 10.1158/2326-6066.CIR-13-0170 Schuberth, 2013, Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells, J Transl Med, 11, 187, 10.1186/1479-5876-11-187 Emtage, 2008, Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation, Clin Cancer Res, 14, 8112, 10.1158/1078-0432.CCR-07-4910 O’Hara, 2017, Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers, Immunotherapy, 9, 767, 10.2217/imt-2017-0026 Ahmed, 2017, HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial, JAMA Oncology, 3, 1094, 10.1001/jamaoncol.2017.0184 Ahmed, 2015, Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial, J Immunother Cancer, 3, 1, 10.1186/2051-1426-3-S2-O11 Brown, 2016, Regression of glioblastoma after chimeric antigen receptor T-cell therapy, N Engl J Med, 375, 2561, 10.1056/NEJMoa1610497 Maus, 2015, Designing CAR T cells for glioblastoma, Onco Immunology, 4, e1048956 O’Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, 9, 10.1126/scitranslmed.aaa0984 Feldmann, 2017, Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”, Oncotarget, 8, 31368, 10.18632/oncotarget.15572 Slovin, 2013, Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC), J Clin Oncol, 31, 72, 10.1200/jco.2013.31.6_suppl.72 Kershaw, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin Cancer Res, 12, 6106, 10.1158/1078-0432.CCR-06-1183 Rafiq, 2017, Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen, Leukemia, 31, 1788, 10.1038/leu.2016.373 Ahmed, 2015, Human epidermal growth factor receptor 2 (HER2) – specific chimeric antigen receptor – modified T cells for the immunotherapy of HER2-positive sarcoma, J Clin Oncol, 33, 1688, 10.1200/JCO.2014.58.0225 van Schalkwyk, 2013, Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer, Hum Gene Ther Clin Dev, 24, 134, 10.1089/humc.2013.144 Jethwa, 2013, Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?, Clin Immunol, 150, 51, 10.1016/j.clim.2013.11.004 Gross, 1989, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc Natl Acad Sci U S A, 86, 10024, 10.1073/pnas.86.24.10024 Hartmann, 2017, Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts, EMBO Mol Med, 9, 1183, 10.15252/emmm.201607485 Singh, 2015, Manufacture of T cells using the sleeping beauty system to enforce expression of a CD19-specific chimeric antigen receptor, Cancer Gene Ther, 22, 95, 10.1038/cgt.2014.69 Eyquem, 2017, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature, 543, 113, 10.1038/nature21405 Poirot, 2015, Multiplex genome-edited T-cell manufacturing platform for “Off-the-Shelf” ADoptive T-cell immunotherapies, Cancer Res, 75, 3853, 10.1158/0008-5472.CAN-14-3321 Thiant, 2010, Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD, Bone Marrow Transplant, 46, 1374, 10.1038/bmt.2010.300 Thiant, 2010, Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse, Bone Marrow Transplant, 45, 1546, 10.1038/bmt.2010.13 Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, New Engl J Med, 368, 1509, 10.1056/NEJMoa1215134 Gauthier, 2017, Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives, Curr Res Transl Med, 65, 93, 10.1016/j.retram.2017.08.003 Park, 2016, CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date, Blood, 127, 3312, 10.1182/blood-2016-02-629063 Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751 Neelapu, 2017, Chimeric antigen receptor T-cell therapy – assessment and management of toxicities, Nat Rev Clin Oncol, 10.1038/nrclinonc.2017.148 Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226 Maude, 2015, CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Blood, 125, 4017, 10.1182/blood-2014-12-580068 Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3 Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309 Frey, 2016, Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia, Hematology Am Soc Hematol Educ Program, 2016, 567, 10.1182/asheducation-2016.1.567 Frey, 2016, Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL), ASCO abstract Turtle, 2015, Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes, ASH Abstract Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222 Cho, 2016, Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab, Bone Marrow Transplant, 51, 1620, 10.1038/bmt.2016.229 Teachey, 2016, Cytokine release syndrome after haploidentical stem cell transplantation, Biol Blood Marrow Transplant, 22, 1736, 10.1016/j.bbmt.2016.08.010 Abboud, 2016, Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated, Biol Blood Marrow Transplant, 22, 1851, 10.1016/j.bbmt.2016.06.010 Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, 7, 303ra139, 10.1126/scitranslmed.aac5415 Gust, 2017, Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov, 10.1158/2159-8290.CD-17-0698 2015 Moreau, 2016, [Transfer of allogeneic stem cell transplant recipients to the intensive care unit: guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)], Bull Cancer, 103, S220, 10.1016/j.bulcan.2016.09.008 Milpied, 2012 Bach, 2017, FDA approval of tisagenlecleucel – promise and complexities of a $475,000, Cancer Drug JAMA Buechner, 2017, Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (All): update to the interim analysis, EHA Abstract Gardner, 2017, Intent to treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208 Brentjens, 2015, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540 Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309 Pan, 2017, High efficacy and safety of low dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients, Leukemia, 10.1038/leu.2017.145 Chang, 2016, Safety and efficacy evaluation of 4SCAR19 chimeric antigen receptor-modified T cells targeting B cell acute lymphoblastic leukemia-three-year follow-up of a multicenter phase I/II study Kochenderfer, 2017, Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels, J Clin Oncol, 35, 1803, 10.1200/JCO.2016.71.3024 Turtle, 2016, Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Sci Transl Med, 8, 355ra116, 10.1126/scitranslmed.aaf8621 Schuster, 2017, Global pivotal phase 2 trial ff the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) – an interim analysis, Hematol Oncol, 35, 27, 10.1002/hon.2437_6 Abramson, 2017, High CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed Car T cell product JCAR017 (TRANSCEND NHL 001), Hematol Oncol, 35, 138, 10.1002/hon.2437_127 Turtle, 2017, Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor – modified T cells after failure of ibrutinib, J Clin Oncol, 35, 3010, 10.1200/JCO.2017.72.8519 Fan, 2017, Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma, ASCO Abstract, 35 Ali, 2016, T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma, Blood, 128, 1688, 10.1182/blood-2016-04-711903 Locke, 2017, Phase I results of ZUMA-1: a multicenter study of KTE-CD19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma, Mol Ther, 25, 285, 10.1016/j.ymthe.2016.10.020